title: [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
abstract: OBJECTIVE
  The combination of irinotecan-bevacizumab is effective in patients with glioblastoma relapse but fatigue is a commonly reported side effect. The objective of this study was to evaluate the level and evolution of fatigue in a series of patients treated with therapeutic combination.
  
  
  METHODS
  We used two self-evaluation tools to quantify the physical and emotional aspects of this fatigue. The Norris Visual Analog Scale (VAS Norris) and the Multidimensional Fatigue Inventory-20 (MFI) tools were undertaken by 39 patients with glioblastoma relapse treated with irinotecan-bevacizumab, initially before the first cycle and thereafter with each cycle up until tumor progression.
  
  
  RESULTS
  Analysis of the results of the VAS Norris scale did not demonstrate an increase in emotional fatigue but did show an increase in physical fatigue that did not reach statistical significance. With regards to the MFI 20 tool, analysis of the results demonstrated a significant increase in general (P=0.0260) as well as physical (P=0.0141) fatigue but there was no difference in the other indices.
  
  
  CONCLUSIONS
  This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab. We suspect that this is as a direct consequence of the treatment. There are however other confounding factors: insidious tumour progression not detected on follow-up imaging or delayed side effects of the initial radiotherapy-chemotherapy.
authors.affiliation: Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 47-83, Boulevard de l'Hôpital, 75651 Paris cedex 13, France. caroline.dehais@psl.aphp.fr
authors.forename: C
authors.initials: C
authors.lastname: Dehais
authors.forename: V
authors.initials: V
authors.lastname: Souvannavong
authors.forename: B K
authors.initials: BK
authors.lastname: Nguyen
authors.forename: N
authors.initials: N
authors.lastname: Jouniaux-Delbez
authors.forename: J-L
authors.initials: JL
authors.lastname: Golmard
authors.forename: C
authors.initials: C
authors.lastname: Tadrist
authors.forename: A
authors.initials: A
authors.lastname: Liou
authors.forename: J-Y
authors.initials: JY
authors.lastname: Delattre
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D059026:Diagnostic Self Evaluation; D005221:Fatigue / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D011795:Surveys and Questionnaires
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin